{"contentid": 487983, "importid": NaN, "name": "Regulatory wobble unnerves Acadia backers", "introduction": "Stumbling 7% before the closing bell on Monday, shares in San Diego\u00e2\u0080\u0099s Acadia Pharmaceuticals fell a further 38% in after-hours trading, following a regulatory setback.", "content": "<p><span style=\"font-weight: 400;\">Stumbling 7% before the closing bell on Monday, shares in San Diego&rsquo;s Acadia Pharmaceuticals (Nasdaq: ACAD) fell a further 38% in after-hours trading, following a regulatory setback.</span></p>\n<p><span style=\"font-weight: 400;\">The company has been told by the US Food and Drug Administration that there is a problem with its supplemental New Drug Application (sNDA) for pimavanserin, a selective serotonin inverse agonist and antagonist, in dementia-related psychosis.</span></p>\n<p><span style=\"font-weight: 400;\">The agency said it had &ldquo;identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time.&rdquo;&nbsp;</span></p>\n<p><span style=\"font-weight: 400;\">Acadia, which has not been told what is lacking from the submission, said it would work with the FDA, to &ldquo;learn the nature of the deficiencies and seek to resolve them.&rdquo;</span></p>\n<p><span style=\"font-weight: 400;\">The FDA made it clear the notification did not reflect a final decision on the information under review, which is due by April 3, 2020.</span></p>\n<h2><strong>Nuplazid development</strong></h2>\n<p><span style=\"font-weight: 400;\">Approved in 2016, Acadia currently markets the atypical antipsychotic as Nuplazid, for the treatment of hallucinations and delusions associated with Parkinson&rsquo;s disease psychosis.</span></p>\n<p><span style=\"font-weight: 400;\">Based on research undertaken in the Phase III HARMONY study, the firm wants to broaden the label to include dementia-related psychosis.</span></p>\n<p><span style=\"font-weight: 400;\">In 2019, Acadia halted the HARMONY study early due to efficacy, the trial meeting its primary endpoint of time to relapse of psychosis, compared to placebo.</span></p>\n<p><span style=\"font-weight: 400;\">The firm&rsquo;s submission in this indication is also backed by Phase II data in people with Alzheimer's disease psychosis and Phase III results in Parkinson's disease psychosis.</span></p>\n<p><span style=\"font-weight: 400;\">Acadia has been met with less success in other areas, however, with </span><a href=\"https://www.thepharmaletter.com/article/acadia-s-pimavanserin-fails-to-meet-ph-iii-goals-in-schizophrenia\"><span style=\"font-weight: 400;\">disappointing results</span></a><span style=\"font-weight: 400;\"> from the Phase III ENHANCE study, which tested pimavanserin in schizophrenia.</span></p>\n<p><span style=\"font-weight: 400;\">Net sales of Nuplazid were $121 million for the fourth quarter of 2020, an increase of 23% on the same period of 2019. For the whole of 2020, the product took in $442 million, an increase of 30%.</span></p>", "date": "2021-03-09 11:50:00", "meta_title": NaN, "meta_keywords": "Acadia, psychosis, regulatory, Phase, Nuplazid, disease, study, Monday, shares, Pharmaceuticals, fell, after-hours, bell, closing, Stumbling, trading, Drug", "meta_description": "Stumbling 7% before the closing bell on Monday, shares in San Diego\u00e2\u0080\u0099s Acadia Pharmaceuticals fell a further 38% in after-hours trading, following a regulatory s", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-09 11:49:35", "updated": "2021-03-09 13:46:51", "access": NaN, "url": "https://www.thepharmaletter.com/article/regulatory-wobble-unnerves-acadia-backers", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "lab_vials_biotech_2021_big.jpg", "image2id": "lab_vials_biotech_2021_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Pharmaceutical", "therapy area_tag": "CNS Diseases, Neurological", "topic_tag": "Drug Trial, Focus On, Regulation, Research, US FDA", "geography_tag": "USA", "company_tag": "ACADIA Pharmaceuticals", "drug_tag": "Nuplazid", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-09 11:50:00"}